VYNE Q2 net loss $5.8M; cash runway extended to H1 2027; two directors resign

VYNE Therapeutics Inc.

2025-Q2 EPS reported -$0.34 revenue$271,000

Cash, equivalents and marketable securities $39.6M as of Jun 30, expected to fund ops into first half of 2027.
Net loss $5.8M ($0.13 per share) vs $9.4M ($0.22) in Q2 2024; revenue $0.1M from Finacea royalty.
Directors Christine Borowski and Anthony Bruno resigned effective Aug 11 and 13, 2025; no dispute with company.
Repibresib Phase 2b vitiligo trial missed primary endpoint; company seeking partner for program.
FDA lifted clinical hold on VYN202 Phase 1b for female subjects; partial hold remains for males pending new toxicology study.

item 2.02item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.